|
Market Closed -
Nasdaq
16:00:00 2026-05-13 EDT
|
5-day change | 1st Jan Change | ||
| 41.03 USD | -0.07% |
|
-.--% | +63.34% |
| Market Cap | 5.25B 4.53B 4.24B 3.87B 7.3B 502B 7.32B 50.35B 19.64B 253B 19.72B 19.29B 840B | P/E 2027 * |
342x | P/E 2028 * | 38.3x |
|---|---|---|---|---|---|
| Enterprise Value | 5.25B 4.53B 4.24B 3.87B 7.3B 502B 7.32B 50.35B 19.64B 253B 19.72B 19.29B 840B | EV / Sales 2027 * |
5.06x | EV / Sales 2028 * | 4.35x |
| Free-Float |
88.57% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript : Apellis Pharmaceuticals, Inc.
| 1 day | -0.07% | ||
| 6 months | +95.75% | ||
| Current year | +63.34% |
| Current year | 16.83 |  | 41.14 |
| 1 year | 16.83 | | 41.14 |
| 3 years | 16.1 | | 73.8 |
| 5 years | 16.1 | | 94.75 |
| 10 years | 11.45 | | 94.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | 56 | 2009-09-24 | |
Timothy Sullivan
DFI | Director of Finance/CFO | 55 | 2017-09-30 |
Leslie Meltzer
CTO | Chief Tech/Sci/R&D Officer | - | 2025-08-24 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/14/26 | Tender | Director | -63,416 | 0.0496% | ||
| 5/14/26 | Tender | Director | -297,904 | 0.2330% | ||
| 5/14/26 | Tender | General Counsel | -928,388 | 0.7263% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.04B 894M 839M 766M 1.44B 99.2B 1.45B 9.95B 3.88B 50.08B 3.9B 3.81B 166B | 1.21B 1.04B 977M 892M 1.68B 116B 1.68B 11.59B 4.52B 58.32B 4.54B 4.44B 193B |
| Net income | -34.31M -29.57M -27.72M -25.31M -47.67M -3.28B -47.82M -329M -128M -1.66B -129M -126M -5.49B | 90.71M 78.16M 73.29M 66.9M 126M 8.67B 126M 869M 339M 4.38B 341M 333M 14.51B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- APLS Stock
Select your edition
All financial news and data tailored to specific country editions
